A Study of SGN-B7H4V in Advanced Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2027-01-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease.

Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

This study will have three parts. Parts A and B of the study will find out how much SGN-B7H4V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe SGN-B7H4V is and if it works to treat solid tumor cancers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seagen Inc.

Criteria

Inclusion Criteria:

• Participants must have one of the following histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor types:

• High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer

• HER2-negative, HR positive breast cancer

• Triple-negative breast cancer (TNBC)

• Endometrial carcinoma

• Squamous non-small cell lung cancer (Sq-NSCLC)

• Cholangiocarcinoma or gallbladder carcinoma

• Parts A and B: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, and, in the judgement of the investigator, should have no appropriate SOC therapeutic option

• Part C: Subjects must have disease that is relapsed or refractory or be intolerant to SOC therapies, unless contraindicated

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Measurable disease per RECIST version 1.1 at baseline

Exclusion Criteria:

• History of another malignancy within 3 years before the first dose of study drug. Any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.

• Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:

• are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment

• have no new or enlarging brain metastases

• and are off corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study treatment.

• Carcinomatous meningitis

• Previous receipt of an MMAE-containing agent or an agent targeting B7-H4

• Pre-existing neuropathy ≥ Grade 2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version5.0

• Corneal disease or injury requiring treatment or active monitoring